INTRODUCTION

Attention-deficit/hyperactivity disorder (ADHD)
is a common neurobehavioral disorder in children [1] . As reviewed by Rader et al., stimulants have been used for decades to treat ADHD symptoms [2, 3] and remain a first-line option [2, 4] . Methylphenidate (MPH) and amphetamine (AMP) psychostimulants have similar subjective effects [5] , but somewhat different mechanisms of action [6] [7] [8] .
The selection of an AMP-or MPH-based medication as the first-choice treatment should be left to the physician, in consultation with the patient and family [9] . ADHD treatment guidelines recommend that, if treatment with one stimulant is ineffective, an alternative stimulant should be attempted before considering second-line therapy [2] . This is supported by crossover trials which suggest that the outcome of treatment with one stimulant is not predictive of that with the other [10, 11] .
However, a greater understanding of the response to treatment in patients who have previously received a different stimulant will further assist prescribers in making informed clinical choices.
Lisdexamfetamine dimesylate (LDX) is a long-acting prodrug stimulant approved for the treatment of ADHD in the United States and Canada for children 6-12 years of age, adolescents 13-17 years of age, and adults. In Europe, LDX is indicated as part of a comprehensive treatment program for ADHD in children aged 6 years and over, when response to previous MPH treatment is considered clinically inadequate. After oral ingestion, therapeutically inactive LDX is converted to l-lysine and active d-AMP in the blood [12] . LDX was designed to have an extended duration, without the need for multiple daily dosing [13, 14] . Clinical trials of LDX have demonstrated short-and long-term efficacy [13] [14] [15] [16] [17] .
In a 7-week, open-label, dose-optimization study (study 1) of children with ADHD [16] , LDX (20-70 mg/day) was effective, as assessed by a clinician-rated symptom scale and by clinician-and parent-rated global measures.
Since many children with ADHD also experience impairments in executive function (EF) [18] and in emotional function across settings [19] , this study measured these impairments at baseline and posttreatment.
The Behavior Rating Inventory of Executive Function (BRIEF) scale [20, 21] examined realworld parent-assessed EF behaviors and the Expression and Emotion Scale for Children (EESC) [22] evaluated parent-rated negative/ positive aspects of emotional expression in children before and during treatment.
Participants significantly improved versus baseline in BRIEF and EESC total and subscale scores following LDX treatment [16] .
Children with ADHD exhibit impairments in the school setting, due to inattention and hyperactivity/impulsivity; therefore, laboratory school models have been used to assess ADHD impact and treatments. A randomized, placebocontrolled, crossover study (study 2) dose-optimization study; and study 2 was a laboratory school study incorporating a 4-week dose-optimization phase, followed by a 2-week, randomized, double-blind, placebo-controlled, crossover period. Both studies enrolled children with a baseline ADHD Ratings Scale IV [25] (ADHD-RS-IV) total score C28, but excluded patients whose pre-study ADHD treatment provided effective control of ADHD symptoms with acceptable tolerability, and patients who had failed to respond to a course of AMP therapy of adequate dose and duration.
The subgroups for the present analyses comprised children who had been treated with MPH (MPH hydrochloride, MPH, or dexmethylphenidate hydrochloride) at any time within the 6-month period immediately prior to study enrollment. If on treatment at screening, participants underwent a washout period of at least 7 days prior to baseline.
Study 1
Study 1 evaluated LDX (20-70 mg/day) efficacy in children (6-12 years) with ADHD with baseline ADHD-RS-IV total score C28 and was described in full previously [16] . The primary efficacy assessment was the change in ADHD-RS-IV total score from baseline to endpoint.
Secondary efficacy measures included the
Clinical Global Impressions (CGI) scale [26], the EESC [22] , and the BRIEF-Parent Form [20] .
ADHD-RS-IV is an 18-item, clinician-rated scale based on criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), with symptoms grouped into two subscales (inattention and hyperactivity/impulsivity) [25, 27] . Each symptom item was scored from 0 (never or rarely) to 3 (very often); total scores ranged from 0 to 54. The CGI global assessments evaluated baseline severity and improvement over time. At baseline, the CGISeverity (CGI-S) scale rated ADHD severity from 1 (normal/not at all ill) to 7 (among the most extremely ill). At all subsequent visits, the CGIImprovement (CGI-I) assessed improvement from 1 (very much improved) to 7 (very much worse). The EESC is a 29-item validated measure of emotional expression; total scores ranged from 29 to 145, higher scores indicating greater impairment [22] . The EESC was administered at baseline and at the final study week. The BRIEFParent Form is an 86-item validated assessment of EF in children (5-18 years) [20, 21] . Global Executive Composite (GEC) scores were transformed to T-scores. T-scores of 50 represent the mean for the normative group distribution [20] . T-scores C65 [C1.5 standard deviation (SD) above the mean] on BRIEF clinical scales and indices were considered potentially clinically significant scores.
Study 2
Study 2, in children (6-12 years) with ADHD and a baseline ADHD-RS-IV score C28, evaluated LDX (30- In addition to a total score, subscores are calculated for deportment and attention [14, 23] . PERMP consists of a 5-page, 80-problem math test, and participants are scored according to the number of problems attempted and the number solved correctly in a 10-min period [24] . SKAMP and PERMP assessments were made 0.5 h pre-dose and 1.5-13.0 h post-dose. ADHD-RS-IV and CGI scores were measured at baseline and at all subsequent weeks, including the two crossover weeks (visits 5/6).
Studies 1 and 2 Analyses
Efficacy outcomes for the overall group were analyzed according to the efficacy population, defined as all randomized participants who received C1 dose of study treatment with C1 available post-randomization measure of the primary efficacy variable. Efficacy outcomes for the study 1 post hoc analysis were for all LDX dose groups combined from baseline to endpoint, defined as the last valid efficacy assessment (i.e., ADHD-RS-IV) post-baseline.
For study 2, efficacy outcomes were reported from baseline to weeks 5 and 6 (visit 5/6), the two crossover phase assessments, for participants taking LDX (all doses) and placebo.
Clinical Response Criteria
A child may exhibit considerable clinical response to treatment from baseline, using the ADHD-RS-IV scale, yet still be symptomatic.
Inclusion of the CGI-I criteria may clinically define how well a participant improved with treatment from baseline, although this child still exhibited ADHD symptoms. A stringent definition for clinical response that combines the two criteria may provide more insight into treatment options for clinicians [28] . For this analysis, clinical responders were classified as participants who achieved at least a 30% reduction in ADHD-RS-IV total score from baseline and a CGI-I score of 1 or 2.
Symptomatic Remission Criteria
There are varying definitions of thresholds to describe ADHD symptomatic remission, which may include clinical response to a degree that the participant no longer exhibits symptoms sufficient to meet DSM-IV-TR criteria [29] . Here, the authors used a conservative definition of symptomatic remission with no symptom item on the ADHD-RS-IV endorsed as more severe than mild [28] . Thus, symptomatic remission was defined as ADHD-RS-IV item scores of B1, for each of the 18 items, at endpoint in study 1 or during the crossover phase of study 2.
Symptomatic remission, as defined in this analysis, may be considered a more stringent definition than that defined in prior LDX studies and analyses (ADHD-RS-IV total score of B18 at endpoint) [30] [31] [32] . An overall score of B18 does not give specific information on the effects of treatment on each individual item, where the participant may still exhibit symptom severity greater than mild on some items.
Written informed consent was obtained from each patient's legal guardian, and assent was obtained from each child prior to study- 
RESULTS
Study 1
Baseline characteristics and demographics of the overall study population have been previously presented [16] . Of 318 enrolled participants, 83 (26.1%) had taken MPH within 6 months of study initiation, 67/83 (80.7%) were treated with long-acting MPH, and 18/83 took C1 mg/kg/day (a dose considered ''generally effective'' [33, 34] . Table 1 shows summary statistics for the dosage and duration of this previous MPH treatment. Children in the prior MPH group had a mean age (SD) of 9.2 (1.88) years, a mean (SD) weight of 33.6 (8.58) kg, and the majority were male (65 of 83, 78.3%), similar to the overall study population. The mean (SD) ADHD-RS-IV baseline total score in this subgroup was 42.6 (6.81) and was similar for males and females with mean (SD) ADHD-RS-IV total scores of 43.0 (6.94) and 41.3 (6.34), respectively.
The mean (SD) change from baseline to endpoint with LDX treatment for ADHD-RS-IV total score was similar for the overall study population and the prior MPH group (Fig. 1) . The mean (SD) relative improvement from baseline to endpoint in ADHD-RS-IV total score for children in the prior MPH group was 64.9% (23.88). Improvement with LDX was numerically greater for males versus females; the relative improvement was 66.3% (23.02) with an endpoint ADHD-RS-IV total score of 14.1 (9.08) for males versus 59.7% (26.80) with an endpoint ADHD-RS-IV total score of 16.6 (11.69) for females. At endpoint, inattention and hyperactivity/impulsivity subscale scores for prior MPH participants were improved overall by 62.7% (26.97) and 67.2% (24.39) from baseline, respectively.
Other secondary efficacy assessments also demonstrated improvement with LDX. Mean (SD) BRIEF GEC scores at baseline and endpoint were similar for the overall study population and prior MPH group (Fig. 2) . Mean (SD) CGI-I scores at endpoint, and EESC total scores, and BRIEF index subscale scores (Behavioral Recognition Index and Metacognition Index) at baseline and endpoint, were similar between the overall study population and prior MPH group (Table 2) . Moreover, with LDX treatment the BRIEF index subscale scores were normalized at endpoint ( Fig. 2 ; Table 2 ).
Rates of symptomatic remission in the overall study population (49.1%) and prior MPH group (42.2%) were similar at endpoint of study 1, although the prior MPH group had numerically lower symptomatic remission rates compared with the overall group, including the subgroups of prior MPH participants with MPH doses \1 or C1 mg/kg/day (Fig. 3) . Moreover, 283 of 316 (89.6%) participants in the overall study population and 72 of 83 (86.7%) prior MPH participants at endpoint achieved clinical response (C30% reduction from baseline in ADHD-RS-IV total score and CGI-I rating of 1 or 2) with LDX.
Study 2
Baseline characteristics and demographics of the overall study population have been previously presented [14] . Of the 129 enrolled participants, 67 (51.9%) had taken MPH within 6 months prior to study entry; all but two were treated with long-acting MPH and 17/67 took C1 mg/kg/day. Table 3 shows summary statistics for the dosage and duration of this previous MPH treatment. In the crossover ADHD-RS-IV baseline total score in this subgroup was 43.1 (7.22) and was similar for males and females with mean (SD) ADHD-RS-IV total scores of 42.6 (7.27) and 45.2 (6.87), respectively.
Change from baseline in mean (SD) ADHD-RS-IV total scores for participants when taking LDX and placebo during the crossover phase were similar for the overall study population (n = 113) and prior MPH group (n = 67) (Fig. 4) .
The mean (SD) relative improvement from baseline to endpoint in ADHD-RS-IV total score for children who had previously received MPH was 57.1% (26.11) in the LDX treatment group and 18.1% (28.85) in the placebo group.
For prior MPH participants who had received average MPH dose C1 mg/kg/day (n = 17), from For prior MPH males, from a mean (SD) baseline score of 42.6 (7.27), the mean (SD) relative improvement in ADHD-RS-IV total scores was 55.3% (27.07) with LDX and 17.6% (29. Both the overall study population and the prior MPH groups performed similarly on the PERMP (Fig. 5c, d) . PERMP-A and PERMP-C scores were improved at all post-dose time points from 1.5 to 13 h with LDX versus placebo (P\0.0001 for all time points in the overall study population and prior MPH participants, respectively, for both PERMP-A and PERMP-C).
At visit 5/6 of the crossover period, mean (SD) CGI-I scores for participants taking LDX and placebo, respectively, were 1.7 (0.9) and 3.5 (1.2) for the overall study population, 1.7 (0.96) and 3.6 (1.14) for prior MPH participants, and 1.7 (0.85) and 3.7 (0.99) for prior MPH participants who had received C1 mg/kg/day MPH.
At visit 5/6 of the crossover phase, 54 of 67 (80.6%) achieved clinical response with LDX and 10 of 67 (14.9%) participants with placebo. Rates of symptomatic remission were similar in the overall study population (LDX 31.9%, placebo 9.7%) and the prior MPH group (LDX 28.4%, placebo 10.4%), including the subgroups of prior MPH participants with MPH doses \1 or C1 mg/kg/day (Fig. 6 ).
Summary of Safety Findings in Study 1 and Study 2
Safety data from both studies have been previously reported [14, 16] 
DISCUSSION
The present analyses did not specifically identify patients whose previous MPH treatment had failed, but did comprise patients who had received any prior MPH treatment within 6 months, and were not excluded on the grounds of adequate symptomatic control and acceptable tolerability with current medication. In studies 1 and 2 [14, 16], LDX effectively reduced ADHD symptoms in children previously treated with MPH within 6 months of study initiation, most of whom were previously treated with longacting MPH. For prior MPH participants, ADHD-RS-IV total scores decreased at endpoint by a mean of 64.9% in study 1. At the end of the crossover phase of study 2, mean ADHD-RS-IV total scores were lower for prior MPH participants receiving LDX (57.1% reduction) and placebo (18.1% reduction). The results were comparable with the overall populations for both studies; however, a trend that suggests a slightly lower reduction in ADHD-RS-IV scores have significantly worse scores on measures of emotional well-being than children without ADHD [19] . Although this has not been established in clinical trials, emotional flattening resulting from stimulants is a concern of clinicians and parents [22] . The magnitude of improvement in the EESC total score for prior MPH children in this analysis was comparable to the overall study. Differential clinical response rates to stimulant treatment are common [10, 11] . Due to suboptimal treatment of ADHD, alternative stimulants should be evaluated to improve patient outcomes [2] . Clinical response rate can be improved to an estimated 92% when stimulants are tried sequentially, after one has failed [10] . There has been limited systematic evaluation of patient outcomes after switching 
